We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Cizzle Biotechnology Holdings Plc | LSE:CIZ | London | Ordinary Share | GB00BNG2VN02 | ORD 0.01P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 1.90 | 1.80 | 2.00 | 1.90 | 1.90 | 1.90 | 327,508 | 07:47:49 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Coml Physical, Biologcl Resh | 0 | -1.72M | -0.0043 | -4.42 | 7.53M |
Date | Subject | Author | Discuss |
---|---|---|---|
03/10/2023 11:39 | How's the OBD short going ;-) | oapknob1 | |
02/10/2023 07:15 | "The test makes use of ProteinSimple's automated and highly sensitive immunoassay technology platform, Simple Western." At a top level what is immunoassay technology ?? ---- Ok, got it ...wonderful Wikipedia! | smithie6 | |
02/10/2023 07:07 | Somebody woke up and said "let's buy some CIZ" it seems .. | dplewis1 | |
01/10/2023 11:24 | Linked in - Bio-Techne love. Could this UK spin-out from University of York hold the key for improved early detection of lung cancer and patient outcomes? DirectorsTalk Interviews spoke to executive chairman Dr. Allan Syms from Cizzle Biotechnology plc about their collaboration with Bio-Techne to develop a new lung-cancer diagnostic test based on immunoassay technology. Cizzle has developed a promising test to detect early-stage disease based on a plasma biomarker, a variant of CIZ1 known as CIZ1B. CIZ1 is a naturally occurring cell nuclear protein involved in DNA replication, and the targeted CIZ1B variant is highly correlated with early-stage lung cancer. The test makes use of ProteinSimple's automated and highly sensitive immunoassay technology platform, Simple Western. This breakthrough comes at a time when the global market for lung cancer screening is expected to grow from US$2.8 billion in 2021 to US$4.85 billion by 2028. Additionally, new US guidelines have expanded the number of people eligible for early lung cancer screening, potentially saving an extra 10,000 to 20,000 lives each year. Congrats to Allan and the Cizzle team and my colleagues in Bio-Techne's analytical solutions division and our Bio-Techne UK office in Oxfordshire. Helen Hall Katie Lloyd #biomarkers #diagnostics #lungcancer | oapknob1 | |
01/10/2023 05:15 | The guy who wrote that first paragraph is Raymond chan of biotechne. No idea why he hides his name but one could imagine. | jimduggen | |
30/9/2023 21:33 | Linked in - Bio-Techne love.Could this UK spin-out from University of York hold the key for improved early detection of lung cancer and patient outcomes? DirectorsTalk Interviews spoke to executive chairman Dr. Allan Syms from Cizzle Biotechnology plc about their collaboration with Bio-Techne to develop a new lung-cancer diagnostic test based on immunoassay technology.Cizzle has developed a promising test to detect early-stage disease based on a plasma biomarker, a variant of CIZ1 known as CIZ1B. CIZ1 is a naturally occurring cell nuclear protein involved in DNA replication, and the targeted CIZ1B variant is highly correlated with early-stage lung cancer. The test makes use of ProteinSimple's automated and highly sensitive immunoassay technology platform, Simple Western.This breakthrough comes at a time when the global market for lung cancer screening is expected to grow from US$2.8 billion in 2021 to US$4.85 billion by 2028.Additionally, new US guidelines have expanded the number of people eligible for early lung cancer screening, potentially saving an extra 10,000 to 20,000 lives each year.Congrats to Allan and the Cizzle team and my colleagues in Bio-Techne's analytical solutions division and our Bio-Techne UK office in Oxfordshire.Helen Hall Katie Lloyd#biomarkers #diagnostics #lungcancerListen to the interview:https://ln | oapknob1 | |
29/9/2023 16:42 | "Apta on the move!!"You got it right for once.It's down you clown! | secretsqu | |
29/9/2023 16:38 | You mean Monday then?? | not guilty | |
29/9/2023 15:04 | Looks like the APTA pumpers backed the wrong pony! These young-ens will never learn. | the imperialist | |
29/9/2023 12:38 | Naff off over there then. | secretsqu | |
29/9/2023 12:23 | ZZZ till next month.Apta!! | thehitman1 | |
29/9/2023 11:23 | Apta on the move!! | thehitman1 | |
29/9/2023 10:26 | He sure can pick-em. I think the other members of the P&D crew left him holding the baby on APTA lol | the imperialist | |
29/9/2023 10:11 | He is down 7% today alone on APTA | ddonaldson2 | |
29/9/2023 10:06 | Pump and dump | moneymachine2 | |
29/9/2023 08:54 | People taking their profits and buying back into Apta. | thehitman1 | |
29/9/2023 08:54 | Pump and dump in play. | thehitman1 | |
29/9/2023 08:47 | MoneyMachine has made his kebab money. Now for the real players to take over. | the imperialist | |
29/9/2023 08:46 | Lol go back to losing money on APTA... | ddonaldson2 | |
29/9/2023 08:45 | Massive sell in the background,by the way. | moneymachine2 |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions